People · Operator
Named in public records as an officer, director or promoter · active 2010–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Novan, Inc. | — | Biotechnology | Series C | $163.9M | $1.3B | 2010 |
John W. Palmour at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John W. Palmour on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert A. Ingram | 1 | 3 |
| Mark Schoenfisch | 1 | 2 |
| G Kelly Martin | 1 | 2 |
| F Neal Hunter | 1 | 2 |
| Nathan Stasko | 1 | 1 |
| Richard Kelly Peterson | 1 | 1 |
| Sean Kelly Murphy | 1 | 1 |
| W Kent Geer | 1 | 1 |
| Robert P Ruscher | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.